Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations
Authors:
- 1 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 64 (5) , 604-616
Abstract
Premature-termination codons (PTCs) in CFTR (cystic fibrosis [CF] transmembrane conductance regulator) result in nonfunctional CFTR protein and are the proximate cause of ∼11% of CF-causing alleles, for which no treatments exist. The CFTR corrector lumacaftor and the potentiator ivacaftor improve CFTR function with terminal PTC mutations and enhance the effect of readthrough agents. Novel correctors GLPG2222 (corrector 1 [C1]), GLPG3221 (corrector 2 [C2]), and potentiator GLPG1837 compare favorably with lumacaftor and ivacaftor in vitro. Here, we evaluated the effect of correctors C1a and C2a (derivatives of C1 and C2) and GLPG1837 alone or in combination with the readthrough compound G418 on CFTR function using heterologous Fischer rat thyroid (FRT) cells, the genetically engineered human bronchial epithelial (HBE) 16HBE14o− cell lines, and primary human cells with PTC mutations. In FRT lines pretreated with G418, GLPG1837 elicited dose-dependent increases in CFTR activity that exceeded those from ivacaftor in FRT-W1282X and FRT-R1162X cells. A three-mechanism strategy consisting of G418, GLPG1837, and two correctors (C1a + C2a) yielded the greatest functional improvements in FRT and 16HBE14o− PTC variants, noting that correction and potentiation without readthrough was sufficient to stimulate CFTR activity for W1282X cells. GLPG1837 + C1a + C2a restored substantial function in G542X/F508del HBE cells and restored even more function for W1282X/F508del cells, largely because of the corrector/potentiator effect, with no additional benefit from G418. In G542X/R553X or R1162X/R1162X organoids, enhanced forskolin-induced swelling was observed with G418 + GLPG1837 + C1a + C2a, although GLPG1837 + C1a + C2a alone was sufficient to improve forskolin-induced swelling in W1282X/W1282X organoids. Combination of CFTR correctors, potentiators, and readthrough compounds augments the functional repair of CFTR nonsense mutations, indicating the potential for novel correctors and potentiators to restore function to truncated W1282X CFTR.Keywords
This publication has 42 references indexed in Scilit:
- Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by IvacaftorAmerican Journal of Respiratory Cell and Molecular Biology, 2014
- NMD: a multifaceted response to premature translational terminationNature Reviews Molecular Cell Biology, 2012
- CFTR: folding, misfolding and correcting the ΔF508 conformational defectTrends in Molecular Medicine, 2012
- Use of Primary Cultures of Human Bronchial Epithelial Cells Isolated from Cystic Fibrosis Patients for the Pre-clinical Testing of CFTR Modulators2011
- Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosisCurrent Opinion in Pulmonary Medicine, 2010
- Restoration of W1282X CFTR Activity by Enhanced ExpressionAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Aminoglycoside antibiotics: old drugs and new therapeutic approachesCellular and Molecular Life Sciences, 2007
- Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicinJournal of Clinical Investigation, 2007
- Cystic FibrosisNew England Journal of Medicine, 2005
- Aminoglycoside AntibioticsAudiology and Neurotology, 2000